Polyrizon Ltd is a clinical development stage biotechnology company focused on innovative nasal hydrogel technologies for respiratory health and protective applications. The company develops medical device hydrogels delivered as nasal sprays that form a thin, bioadhesive barrier in the nasal cavity, designed to act as a “biological mask” against a broad range of airborne viruses, allergens, and other environmental particles. Its core Capture and Contain platform uses naturally occurring building blocks to create a shield that helps limit contact between inhaled agents and nasal epithelial tissue. In parallel, Polyrizon Ltd is advancing its Trap and Target technology, aimed at intranasal delivery of active pharmaceutical ingredients for potential therapeutic use. Operating today from its headquarters in Raanana, Israel, and founded in 2005, the company occupies a niche at the intersection of medical devices and drug delivery systems, serving healthcare markets that seek non-systemic, preventive, and supportive nasal solutions for infectious disease exposure and allergy management.